Home » Healthcare » Pharmaceuticals » Nosocomial Infection Treatment Market

Nosocomial Infection Treatment Market By Infection (Ventilator Associated Pneumonia, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, Gastrointestinal Infection, MRSA), By Treatment (Antibacterial Treatment, Antiviral Treatment, Antifungal Treatment) – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2024

Price: $4999

Published: | Report ID: 14189 | Report Format : PDF

Market Insights

The World Health Organization defines nosocomial infection as “an infection acquired in hospital by a patient who was admitted for a reason other than that infection.” an infection occurring in a patient in a hospital or other healthcare facility in whom the infection was not present or incubating at the time of admission. This includes infections acquired in the hospital but appearing after discharge, as well as occupational infections among the staff of the facility.

The infection is caused by bacteria, viruses, fungi, and parasites. Because of an extended stay in the hospital, the use of indwelling catheters, some failure on the part of the health care provider, or an antibiotic overdose, all hospital patients are susceptible to infection, particularly pediatric and geriatric patients and immune-compromised patients. The global nosocomial infection treatment market is anticipated to progress during the forecast period due to the rising prevalence of nosocomial infections, an increase in the number of surgical procedures, and an escalating focus on disinfection and sterilization technology.

The report titled “Global Nosocomial Infection Treatment Market: Growth, Share, Opportunities, and Competitive Analysis, 2016–2024” offers strategic insights into the overall nosocomial infection treatment market, along with the market size and estimates for the duration of 2014 to 2024. The study provides an in-depth analysis of multiple market segments based on product type and geography.

The infection types studied for analyzing the overall nosocomial infection treatment market are majorly segmented into ventilator-associated pneumonia, urinary tract infection, bloodstream infection, surgical site infection, MRSA, and others. The treatment types considered for analyzing the market are antibacterial, antifungal, antiviral, and others.

Geographically, the global nosocomial infection treatment market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

The market size and forecast for these regional and country-level markets are presented in this study for the period 2014–2024. Market growth rates for the forecast period 2016–2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global nosocomial infection treatment market.

Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global nosocomial infection treatment market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global nosocomial infection treatment market. In-depth competitive environment analysis and historic market size data are also provided in the report.

Based on the type of infection, the global nosocomial infection treatment market is segmented as follows:

  • Ventilator-Associated Pneumonia
  • Infection of the Urinary Tract
  • bloodstream infection
  • Surgical site infection
  • Gastrointestinal Infection
  • MRSA
  • Others (ENT infections, skin infections, and bone infections)

Pneumonia and surgical site infections are the most common hospital-acquired infections, occupying the largest market share. Nosocomial pneumonia is observed in several varied groups. The patients on ventilators in the ICU are more susceptible to infection; the rate of infection caused by pneumonia is 3% per day and is associated with a high fatality rate. Surgical site infection is the next big concern, with the incidence rate varying from 0.5% to 15%, depending on the type of operation and patient status. Bloodstream infection accounts for almost 15% to 20% of nosocomial infections, affecting almost 1% of all hospitalized patients.

It is associated with an increased mortality rate and an extended stay in an intensive care unit and hospital; therefore, surveillance and prevention of BSI are high priorities. Urinary tract infection occurs due to the use of a bladder catheter and is associated with less morbidity compared to other nosocomial infections. MRSA is the second most common cause of HAIs reported to the NHSN. The CDC also estimates that 49% to 65% of hospital-acquired S. aureus infections reported to the NHSN are caused by methicillin-resistant strains.

Based on the type of treatment, the global nosocomial infection treatment market is segmented as follows:

  • Antibacterial Treatment
  • Antiviral Treatment
  • Antifungal Treatment
  • Others

Because of the risk of emergence of emergency situations, infection severity in neutropenia, and the large presence of immunocompromised and elderly patients, antibiotic therapy is empirical in the intensive care unit. The selection of antibiotic therapy depends upon the most common bacterial species causing infection, the pattern of antibiotic resistance in a particular hospital, the clinical status of the patient, and previous therapy.

It covers both gram-positive and gram-negative bacteria. Initial antibiotic therapy includes ceftazidime plus vancomycin; if vancomycin is not used, monotherapy with ceftazidime, imipenem, cefepime, or meropenem is given. Multiple antibiotics are used when the organism develops a resistant mutant, the patient is immunocompromised, higher serum activity is required, or the blood culture consistently shows positive bacteria even after a single therapy. The conventionally long-used initial regimen of combination therapy recommended includes antipseudomonal penicillin plus aminoglycoside or an antipseudomonal cephalosporin (ceftazidime) plus an aminoglycoside. Antifungal drugs are used to treat fungal infections.

These include amphotericin B, nystatin, ketoconazole, itraconazole, and fluconazole. Antiviral drugs used are acyclovir, ganciclovir, foscarnet, and amantadine, which inhibit the growth or multiplication of the virus. Empiric antibiotics, antivirals, and antifungals are used to treat infection and avoid any further complications, including organ damage.

Geographically, the global nosocomial infection treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

North America currently dominates the regional global nosocomial infection market, followed by Europe. The key drivers for the North American market are the rising prevalence of nosocomial infections, multi-drug-resistant microbes, and rising demand for advanced therapeutics.

The U.S. is the major market in North America due to incessant technological advancements in surgical procedures, sterilization equipment, and state-of-the-art healthcare facilities. Europe is the second largest market, owing to an increase in the geriatric population, which is susceptible to nosocomial infection, government initiatives to improve healthcare facilities, and advances in antimicrobial therapeutics.

Asia Pacific is the fastest growing market due to factors such as increasing investment in healthcare facilities, a rise in per capita income fueled by economic development, huge government investments in the development of healthcare infrastructure, and rising public awareness coupled with a high prevalence of nosocomial infection.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Nosocomial Infection Treatment Portraiture
2.2 Global Nosocomial Infection Treatment Share, by Infection Type, 2015 (US$ Mn)
2.3 Global Nosocomial Infection Treatment, by Treatment Type, 2015 (US$ Mn)
2.4 Global Nosocomial Infection Treatment, by Geography, 2015 (Value %)

Chapter 3 Global Nosocomial Infection Treatment Analysis
3.1 Global Nosocomial Infection Treatment Overview
3.2 Epidemiology of Nosocomial Infections
3.3 Guidelines for Nosocomial Infection Control
3.4 Market Dynamics
3.4.1 Market Drivers
3.4.2 Challenges
3.4.3 Opportunities
3.5 Attractive Investment Proposition, 2015
3.6 Market Positioning Analysis of Key Players: Nosocomial Infection Treatment Market, 2015

Chapter 4 Global Nosocomial Infection Treatment Analysis, by Infection Type, 2014-2024 (US$)
4.1 Introduction
4.2 Ventilator Associated Pneumonia
4.3 Urinary Tract Infection
4.4 Blood Stream Infection
4.5 Surgical Site Infection
4.6 Gastrointestinal Infection
4.7 MRSA
4.8 Others (ENT Infections, Skin Infection, and Bone Infection)

Chapter 5 Nosocomial Infection Treatment Analysis, by Treatment Type, 2014-2024 (US$)
5.1 Introduction
5.2 Antibacterial Treatment
5.3 Antiviral Treatment
5.4 Antifungal Treatment
5.5 Others

Chapter 6 Global Nosocomial Infection Treatment, by Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan, and Rest of APAC)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Abbott
7.2 Bayer
7.3 Becton, Dickinson and Company
7.4 Belimed
7.5 BioMerieux
7.6 Cantel
7.7 Cepheid
7.8 Getinge Group
7.9 Kimberly-Clark Corp.
7.10 Merck & Co
7.11 Nordion
7.12 Pfizer
7.13 Roche
7.14 Sakura Seiki
7.15 BioMérieux
7.16 Steris
7.17 Johnson & Johnson
7.18 Sterigenics International, Inc.
7.19 Halyard Health, Inc.
7.20 Advanced Sterilization Products
7.21 Matachana Group
7.22 Other Notable Players

List of Figures

FIG. 1 Global Nosocomial Infection Treatment: Research Methodology
FIG. 2 Global Nosocomial Infection Treatment Share, by Infection, 2015 (US$ Mn)
FIG. 3 Global Nosocomial Infection Treatment, by Application Type, 2015 (US$ Mn)
FIG. 4 Global Nosocomial Infection Treatment, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition: Global Nosocomial Infection Treatment, by Geography
FIG. 6 Competitive Analysis: Key Players in Global Nosocomial Infection Treatment
FIG. 7 Global Ventilator Associated Pneumonia Market, 2014 – 2024 (US$ Mn)
FIG. 8 Global Urinary Tract Infection Market, 2014 – 2024 (US$ Mn)
FIG. 9 Global Blood Stream Infection Market, 2014 – 2024 (US$ Mn)
FIG. 10 Global Surgical Site Infection Market, 2014 – 2024 (US$ Mn)
FIG. 11 Global Gastrointestinal Infection Market, 2014 – 2024 (US$ Mn)
FIG. 12 Global MRSA Market, 2014 – 2024 (US$ Mn)
FIG. 13 Global Others (ENT Infections, Skin Infection, and Bone Infection) Market, 2014 – 2024 (US$ Mn)
FIG. 14 Global Antibacterial Treatment Market , 2014 – 2024 (US$ Mn)
FIG. 15 Global Antiviral Treatment Market, 2014 – 2024 (US$ Mn)
FIG. 16 Global Antifungal Treatment Market, 2014 – 2024 (US$ Mn)
FIG. 17 Global Other Treatment Market, 2014 – 2024 (US$ Mn)

List of Tables

TABLE 1 Global Nosocomial Infection Treatment, By Infection Type 2014-2024 (US$ Mn)
TABLE 2 Nosocomial Infection Treatment, by Treatment Type , 2014-2024 (US$ Mn)
TABLE 3 Global Nosocomial Infection Treatment, by Geography, 2014 – 2024 (US$ Mn)
TABLE 4 North America Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 5 Europe Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 6 Asia-Pacific Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 7 Latin America Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 8 Middle East and Africa Nosocomial Infection Treatment, by Country, 2014 – 2024 (US$ Mn)
TABLE 9 Abbott, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 10 Bayer, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 11 Becton, Dickenson and Company: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 12 Belimed: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
TABLE 13 BioMerieux: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 14 Cantel: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Cepheid: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Gettinge Group: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 17 Kimberly- Clark Corp.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 U Merck & Co: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Nordion: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 Pfizer: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 Roche: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 22 Sakura Seiki: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 23 BioMérieux: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 24 Steris: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 25 Johnson & Johnson: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 26 Sterigenics International, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 27 Halyard Health, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 28 Advanced Sterilization Products: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 29 Matachana Group: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

Frequently Asked Questions:

What is the size of Nosocomial Infection Treatment Market?

The market for Nosocomial Infection Treatment Market is expected to reach US$ 36,746 Mn By 2024.

What is the Nosocomial Infection Treatment Market CAGR?

The Nosocomial Infection Treatment Market is expected to see significant CAGR growth over the coming years, at 2.5%.

What is the Forecast period considered for Nosocomial Infection Treatment Market?

The report is forecasted from 2016-2024.

What is the base year considered for Nosocomial Infection Treatment Market?

The base year of this report is 2015.

Who are the major players in this market?

Becton, Dickinson and Company, Kimberly-Clark Corp., Sterigenics International, Inc., Sakura Seiki are some of the major players in the global market.

U.S. 503b Compounding Pharmacies Market

Published:
Report ID: 15988

Inulin Market

Published:
Report ID: 11192

Drug Discovery Market

Published:
Report ID: 38270

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Japan’s Pharmacy Automation Market

Published:
Report ID: 37511

Sterile Active Pharmaceutical Ingredient Market

Published:
Report ID: 37476

Organ Preservation Solutions Market

Published:
Report ID: 37472

Middle East and Africa Veterinary Vaccines Market

Published:
Report ID: 37309

Asia Pacific Stem Cell Therapy Market

Published:
Report ID: 37280

US Active Pharmaceutical Ingredient (API) Market

Published:
Report ID: 37221

Cancer Supportive Care Market

Published:
Report ID: 1901

Middle East and Africa Radiopharmaceuticals Market

Published:
Report ID: 37164

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN